Health5 hours ago
EyePoint Pharmaceuticals Secures $150 Million for DURAVYUTM
EyePoint Pharmaceuticals has successfully priced its latest underwritten public offering at $12.00 per share, aiming to raise approximately $150 million in gross proceeds. The funds will...